are you prepared for the new wave of adcs in nsclc? targeting her2, her3, trop2, and others
Published 1 year ago • 5.1K plays • Length 56:23Download video MP4
Download video MP3
Similar videos
-
58:30
the potential of her2-, her3-, and trop2-targeted therapies to address unmet needs in advanced nsclc
-
58:27
addressing key targets in advanced nsclc: her2-, her3-, and trop2-targeted therapies
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
1:27:49
biomarker testing for new therapeutic options targeting her2, her3, and trop2 in solid tumors
-
1:05:01
tackling the practicalities of antibody–drug conjugate therapy for solid tumors
-
49:56
reshaping the future of lung cancer treatment with trop2-targeting adcs and rational combinations
-
1:00:29
answers to key questions about antibody–drug conjugates in nsclc
-
48:40
taking aim with the next wave of antibody–drug conjugates in nsclc to address unmet needs
-
1:37:33
amplifying the adc advantage: adcs as the next frontier in precision lung cancer care
-
1:29:20
experts discuss antibody-drug conjugates in breast, lung, & gi cancers - https://bit.ly/3rkkvzm
-
1:33
antibody-drug conjugates (adcs) in nsclc
-
40:12
improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates
-
50:09
community context: integrating trop2-targeting adcs into patient-centric breast cancer care
-
3:58
antibody drug conjugates in lung cancer
-
2:07
emerging toxicities associated with adcs
-
1:59
developments in adcs for nsclc
-
1:25
targeting egfr-positive nsclc with antibody-drug conjugates
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
1:58
the role of antibody drug conjugates in lung cancer care